News

The U.S. Food and Drug Administration (FDA) has told Sunovion Pharmaceuticals that it is unable to approve APL-130277 (apomorphine sublingual film) in its present form for the treatment of Parkinson’s disease “off”  periods. Sunovion submitted new drug application for APL-130277 in April 2018. Now the FDA has now…

An investigational gene therapy was able to preserve nerve axons — long projections that connect nerve cells and transport information — in a mouse model of severe axonal degeneration. Because axon degeneration precedes the death of neurons in several neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), the findings…

The hallmark presence of Lewy bodies in the pathway related to sense of smell and in the gut years before a Parkinson’s diagnosis, as well as the potential cumulative impact of different triggers, may help researchers understand the environmental factors that contribute to the development of the disease, according…

Neurocrine Biosciences and Voyager Therapeutics have joined efforts in a new strategic collaboration to further develop and market Voyager’s gene therapies VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia. With this partnership, Neurocrine Biosciences will apply its expertise in neuroscience, drug development, and…

Parkinson’s disease patients with mild cognitive impairment who undergo deep brain stimulation are at a higher risk of cognitive decline and dementia, a long term “real-life”study suggests. The study, “Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson’s disease,” was…

A “PACT” formed by the Parkinson’s community — to prevent, advocate for increased resources, care for all those affected, and treat with new therapies — may help prevent a Parkinson’s pandemic, according to a review study. The study, “The Emerging Evidence of the Parkinson Pandemic,” appeared in…

This year, Parkinson Voice Project (PVP) is broadening its SPEAK OUT! & LOUD Crowd Grant Program to include support for international speech therapy clinics. The expanded grant program is intended to help Parkinson’s disease patients around the world gain access to quality speech treatment to maintain their speaking abilities and…

Toxic protein aggregates called Lewy bodies sequestrate a protein that is usually found in the cell nucleus and known to protect against neurodegeneration, and change in this protein’s location contributes to the mechanisms underlying Parkinson’s disease, researchers report. The study, “Loss of nuclear REST/NRSF in aged-dopaminergic neurons in…

Use of dopamine agonists, earlier disease onset, being male, and having personality traits such as impulsiveness and high novelty-seeking are among the risk factors for developing impulse control disorders (ICDs) in people with Parkinson’s, according to a review study. The research, “Impulse control disorders in Parkinson’s…

Genes that control a molecular pathway responsible for moving biological cargo into cells contribute to the risk of developing Parkinson’s disease, researchers report. The study, “The Endocytic Membrane Trafficking Pathway Plays a Major Role in the Risk of Parkinson’s Disease,” was published in Movement Disorders. The movement of…